Progress in precision #oncology depends on shared resources. @eaonc.bsky.social researchers are partnering with Caris Life Sciences to profile paired primary and recurrent breast tumors from two landmark trials, TAILORx and RxPONDER. During #BreastCancerAwareness learn more: bit.ly/ea1241-blog

The EA5221/ACHIEVE clinical study is testing two different treatment approaches for older adults with advanced non-small cell #LungCancer. Learn more: https://bit.ly/ea5221-achieve #NSCLC #LCSM

EA1241, led by Dr. Joseph Sparano, is a companion study for patients who previously took part in either the TAILORx (PACCT-1) or RxPONDER (S1007) breast cancer trials. Learn more: https://bit.ly/EA1241

#FindingsFriday: Don’t miss the newest round-up of recently published findings from @eaonc.bsky.social #ClinicalTrials. See key #CancerResearch results and why they matter: bit.ly/3VUTsIs

Can patients with high anatomic risk but low genomic risk for early-stage ER+/HER2- #breastcancer do similarly well without #chemotherapy? A new @eaonc.bsky.social #trial aims to evaluate the benefits for this subgroup.

Only about 7% of US patients with #cancer take part in #ClinicalTrials, and distance is a major barrier. Cooperative groups supported by The NCI's Community Oncology Research Program help bring trials to community sites closer to home. Learn more: bit.ly/3TqHCVU

Monika Joshi, MD and Petros Grivas, MD, PhD are leading clinical trial EA8231, a phase 3 randomized trial comparing the effectiveness of pembrolizumab and sacituzumab govitecan to standard-of-care chemotherapy in patients with advanced urothelial cancer. https://bit.ly/ea8231-study

Consistent, evidence-based funding has helped deliver major advances in #cancer treatment. @acscan.bsky.social shares its perspective on a reported change to #NIH grantmaking and what it could mean for research: bit.ly/4xPN16S

The #BreastCancer study EA1242/RxFINE-Low is testing whether hormone therapy plus ribociclib, without chemotherapy, is as effective as standard treatment that includes chemotherapy. Learn more: https://bit.ly/ea1242-study

#ClinicalTrial EA5221/ACHIEVE, led by Dr. Megan Baumgart, aims to help older patients with #LungCancer live longer while also maintaining a good quality of life. Learn more: https://bit.ly/ea5221-achieve #NSCLC #LCSM

#ClinicalTrial EA7211/STRASS 2, led in the US by Dr. Kenneth Cardona, is the second randomized study ever performed in retroperitoneal soft tissue #sarcoma & is enrolling patients in the US, Europe, Canada, Australia, New Zealand, & Japan! Learn more: https://bit.ly/EA7211

#FindingsFriday: New research from 9 ECOG-ACRIN Cancer Research Group trials found most patients who smoked before their #cancer diagnosis kept smoking—during and after treatment. #SmokingCessation support needs to be built into cancer care, not left to chance. Learn more: https://bit.ly/4dvJZxj

ICYMI, more than a decade after TAILORx changed #BreastCancer care, its biorepository is yielding new insights: researchers used #AI to review archived pathology slides from 4,000+ trial participants, developing a more accurate recurrence-risk model. More: https://bit.ly/4cY42EB

EA8231 is a phase 3 study comparing pembrolizumab & sacituzumab govitecan versus standard chemotherapy in patients with advanced urothelial cancer. The trial aims to improve treatment options & guide further research. ➡️ https://bit.ly/ea8231-study

Decades of federal investment in #CancerResearch have saved millions of lives. American Association for Cancer Research (AACR)'s Cancer Progress Report asks Congress to sustain NIH/NCI funding & protect grants from interference—because progress against #cancer depends on it. https://bit.ly/4xC3bRk

Do you have #BreastCancer that was recently removed by surgery? If so, you may be eligible for clinical trial EA1242/RxFINE-Low, a study exploring potential new treatment approaches. More info: https://bit.ly/ea1242-study

Do you have advanced non-small cell #LungCancer and are age 70 or older? If so, you may be able to participate in this study of a new treatment approach. Learn more: https://bit.ly/ea5221-achieve

Can patients with high-risk retroperitoneal #sarcoma benefit from neoadjuvant chemotherapy? The international EA7211/STRASS 2 #ClinicalTrial, led in the US by Dr. Kenneth Cardona aims to find out. More: https://bit.ly/EA7211 cc: European Organisation for Research and Treatment of Cancer

#FindingsFriday: New results from CompassHER2 pCR help identify factors associated w/ pathologic complete response in HER2+ #BreastCancer. Research like this moves us closer to more personalized treatment strategies. More in JCO Journals: https://bit.ly/4hqJjM3 #ClinicalTrials